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Available online 22 December 2012Spinal muscular atrophy (SMA), a genetic neurodegenerative disorder, is caused by mutations or deletions in the
survival of motor neuron 1 (SMN1) gene that result in SMN deﬁciency. SMN deﬁciency impairs microtubule net-
works in Smn-deﬁcient cells and in SMA-likemotor neuron cultures. Microtubule defects can be restored by knock-
down of the stathmin gene (Stmn), which is upregulated in SMA. However, whether in vivo reduction of stathmin
levels could improve the pathology of SMA has not been investigated. Here we generated SMA-like mice in a Stmn
knockout (KO) background through a series of genetic crosses. Analyses of motor performance and histology
showed that heterozygous StmnKO (Stmn+/−) but not homozygous StmnKO (Stmn−/−) ameliorates some SMA de-
fects, with increased microtubule densities in sciatic axons, improved motor performance, enhanced NMJ matura-
tion, and mitigated neuroinﬂammation. However, Stmn deletion does not prolong the lifespan of SMA-like mice,
suggesting that stathmin dysregulation and microtubule disruption are not a cause but rather a consequence of
SMApathology. Thiswork demonstrates that limiting the amount of stathmin in SMA-likemice is effective in reduc-
ing their neuromuscular defects, whereas induced aberrant expression of stathmin in SMA-like animals is
detrimental.
© 2012 Elsevier Inc.Open access under CC BY-NC-ND license. Introduction
Spinal muscular atrophy (SMA) is an incurable neurodegenerative
disorder characterized by α-motor neuron death, which leads to pro-
gressive muscle weakness and paralysis (Pearn, 1980). SMA is caused
by homozygous deletion or loss-of-function mutations in the human
survival of motor neuron gene 1 (SMN1) (Brzustowicz et al., 1990;
Bussaglia et al., 1995; Clermont et al., 1995; Lefebvre et al., 1995).
The paralogue gene, SMN2, cannot compensate for the loss of SMN1
due to a C-to-T transition in exon 7. The resulting SMN transcript
lacks exon 7 and thus produces an unstable, C-terminal truncated
SMN protein (Lorson et al., 1999; Monani et al., 1999). The copy num-
ber of SMN2 determines the residual SMN level, which correlates with
the disease severity (Coovert et al., 1997; Lefebvre et al., 1997) as
conﬁrmed in SMA mouse models (Frugier et al., 2000; Hsieh-Li et
al., 2000; Monani et al., 2000).
The ubiquitously expressed SMN protein is involved in the small nu-
clear ribonucleoprotein (snRNP) assembly machinery, which controls
pre-mRNA splicing (Liu and Dreyfuss, 1996; Liu et al., 1997; Meister et
al., 2001; Pellizzoni et al., 1998, 2002). SMN deﬁciency causes wide-
spread splicing abnormalities in the SMA mouse model (Zhang et al.,), mbsue@gate.sinica.edu.tw
w.sciencedirect.com).
NC-ND license. 2008). In addition, SMNmay exert some neuron-speciﬁc functions. Neu-
rons with SMN deﬁciency have several defects, including decreased
axon outgrowth (Rossoll et al., 2003; Ting et al., 2007), impaired
axon path-ﬁnding (McWhorter et al., 2003), dysregulation of actin
dynamics (Bowerman et al., 2007; Rossoll et al., 2003), defects in
presynaptic organization (Torres-Benito et al., 2011), and disrup-
tion of microtubule networks (Wen et al., 2010).
A microtubule destabilizing protein, stathmin/Op18, is a ubiquitous
phosphoprotein that has a high expression during the development of
the nervous system and becomes downregulated following terminal dif-
ferentiation (Doye et al., 1989; Koppel et al., 1990; Peschanski et al.,
1993). The differential phosphorylation of stathmin controlsmicrotubule
dynamics (Larsson et al., 1997; Marklund et al., 1996). We have previ-
ously shown that stathmin is dysregulated in SMA mice (Wen et al.,
2010). Knockdown of Stmn expression in SMA-like cells ameliorates de-
fects in organelle transport and in the outgrowth of axons and microtu-
bules (Wen et al., 2010).
In this study, the role of stathmin in the progression of SMA was
investigated by back-crossing SMA-like mice into Stmn knockout
(KO) mice. Our results show that StmnKO did not prolong the
lifespan of SMA-like mice. However, SMA-Stmn+/− mice had im-
proved body weight gain, motor performance, and neuromuscular
junction (NMJ) maturation. This improvement in neuromuscular
pathology was likely due to a recovery of microtubules in axons, in-
dicating a role for stathmin in the pathogenesis of motor axonal de-
fects in SMA.
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Mice
SMA-like mice and Stmn−/− mice were generated as previously
described (Hsieh-Li et al., 2000; Liedtke et al., 2002). SMA-like mice
with a StmnKO background were generated by a series of genetic
crosses as described in Fig. 1. Brieﬂy, late-onset type III SMA-like
mice (Smn−/−SMN2+/+, carrying 4 copies of SMN2) and the hetero-
zygous SmnKO mice (Smn+/−) were backcrossed respectively with
Stmn+/− mice. The offspring with different genotypes (milder type
III SMA mice, Smn−/−Stmn+/−SMN2+/+; and Smn-Stmn KO mice,
Smn+/−Stmn+/−) were then backcrossed with each other. Stmn−/−
mice were initially maintained in the C57BL/6L strain; therefore, we
backcrossed these mice to the FVB strain for six generations. Each al-
lele was genotyped by using allele-speciﬁc primers (Hsieh-Li et al.,
2000; Liedtke et al., 2002).
Western blot analysis
Mouse tissues were homogenized or lysed in a RIPA buffer
(150 mM NaCl, 50 mM Tris/HCl at pH 8.0, 2 mM EDTA, 0.5% sodiumFig. 1. Generation of stathminKO SMA-like mice. (A) The breeding scheme for generating S
SMN2+/+ mice. These mice were then mated with Smn+/−Stmn+/− mice to generate the
[Smn−/−Stmn+/+(or Stmn+/− or Stmn−/−)SMN2+/−]. (B) PCR assay to conﬁrm the genotyp
of mice. β-Actin was used as an internal control. (D) Quantitative analysis of stathmin level i
are reported as the mean±S.E.M. Note: The stathmin level in SMA-Stmn+/+ is higher than th
detectable.deoxycholate, 1% Nonidet P-40, 1 mM Na3VO4, 50 mM NaF) sup-
plemented with a protease inhibitor cocktail (Merck, Darmstadt,
Germany). Equal amounts of boiled lysate were separated on SDS-
polyacrylamide gels and then transferred to PVDF membranes. The
membranes were incubated in a blocking solution (0.1 M PBS, 5%
non-fat milk, 0.2% Tween-20) for 1 h at room temperature and then
incubated in the same solution with the appropriate primary or sec-
ondary antibody. Finally, the membranes were visualized by using
enhanced chemiluminescence (ECL; Perkin Elmer Life Sciences,
Boston, MA). Relative densitometric values in western blots were an-
alyzed by using AlphaEaseFC software (Alpha Innotech Corporation,
San Leandro, CA).
Histological examination of spinal cord motor neurons
Lumbar spinal cords were ﬁxed in 4% paraformaldehyde (PFA) and
dehydrated in a series of sucrose solution. After serial sectioning at
60 μm intervals, the sections (10 μm each) were stained with Cresyl
violet. Images were acquired by using a Zeiss Axio Image Z1 micro-
scope (Carl Zeiss, Germany) with a 20× objective. Motor neuron
numbers were quantiﬁed by using Image-Pro Plus software (version
6, Media Cybernetics, Silver Springs, MD).tmnKO SMA-like mice. Several cross-mating steps are required to get Smn+/−Stmn+/−
control mice [Smn+/−Stmn+/+(or Stmn+/− or Stmn−/−)SMN2+/−] and SMA-like mice
e of mice in each group. (C) Western blot indicates the stathmin level in each genotype
n (C), showing that stathmin levels correlated with the Stmn genotypes (N=5). Results
at in the control-Stmn+/+. ⁎⁎P=0.093; n.s., not signiﬁcant by Student's t-test; N.D., not
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Lumbar spinal cord cryosections (10 μm) were blocked and in-
cubated with the glial ﬁbrillary acid protein (GFAP) antibody
(Merck Millipore), followed by incubation with Alexa Fluor 488
donkey anti-rabbit IgG (Molecular Probes, Invitrogen, Carlsbad,
CA). Finally, samples were stained with DAPI (Sigma) for 5 min to
identify nuclei and then mounted with a ﬂuorescence mounting
solution (Invitrogen). Confocal images were obtained by using a
LSM710 microscope (Carl Zeiss) with a 20× objective.
Assessment of motor performance
The Tube assay was measured as previously described (El-Khodor
et al., 2008). Brieﬂy, mice were placed on a 50 mL plastic centrifuge
tube by their hind-limbs and scores assigned based on the following
criteria: score of 4, normal hind-limb separation with tail raised;
score of 3, hind-limbs are closer together without touching each
other; score of 2, hind-limbs are closer together and often touch
each other; score of 1, hind-limbs are clasped with tail raised; and
score of 0, hind-limbs are constantly clasped with the tail lowered.
Whole-mount staining
For whole-mount immunostaining, the gastrocnemius and tibialis
anterior muscles were dissected out and ﬁxed in 4% PFA for 2 h at
4 °C. After extensive washing in 0.1 M PBS/0.1 M glycine 3 times,
the muscles were blocked in a blocking buffer (3% BSA and 0.5%
Triton-X100 in 0.1 M PBS), followed by incubation with anti-
Neuroﬁlament H antibody (diluted to 1:1000; Merck Millipore) in
a blocking solution overnight at 4 °C. The following day, samples
were washed in ﬁve changes of rinse solution (1% BSA, 0.5%
Triton-X100 in 0.1 M PBS) over 5 h, and then incubated with
Alexa Fluor 488 donkey anti-rabbit IgG and TRITC-conjugated
α-bungarotoxin (α-BTX) (diluted to 1:1000; Molecular Probes,
Invitrogen). After washing with ﬁve changes of rinse solution
over a period of 5 h, muscle samples were mounted onto slides by
using ﬂuorescence mounting solution (Invitrogen). Confocal
images were captured by using a LSM710 microscope (Carl Zeiss)
with a 25× objective. NMJ area measurements were made by
using MetaMorph software (version 7.7, Molecular Devices,
Downington, PA).
Electron microscopy
The sciatic nerves were ﬁxed with 4% PFA and 2.5% glutaraldehyde
in sodium cacodylate buffer. After extensive washing in sodium
cacodylate buffer, the tissues were post-ﬁxed in 1% osmium tetroxide
in sodium cacodylate buffer. Following dehydration, the tissues were
embedded in Spurr resin. Ultra-thin sections were stained with
uranylacetate and lead citrate and then viewed by using a Tecnai
G2Spirit Twin electron microscope (FEI Company, Hillsboro, OR). Mi-
crotubule densities were measured by using MetaMorph software
(Molecular Devices).
Results
Generation of StmnKO SMA-like mice
A previous study has shown that the aberrant expression of Stmn
in SMA-like mice correlates with SMA disease severity (Wen et al.,
2010). To further investigate whether a decrease in stathmin levels
prevents the development of SMA pathology, a series of genetic
crosses of mice was conducted to generate SMA-like mice with a
StmnKO background (Fig. 1A, detailed description is shown in the
Materials and methods section). To minimize the effects caused bydifferent genetic backgrounds, StmnKO mice were backcrossed for
six generations into the FVB background. The sixth generation of off-
spring carrying heterozygous Smn-StmnKO (Smn+/−Stmn+/−) were
intercrossed with type III SMA-like mice with a Stmn+/− background
(Smn−/−Stmn+/−SMN2+/+) to obtain SMA-like mice with or without
Stmn expression (SMA-Stmn+/+, SMA-Stmn+/−, and SMA-Stmn−/−)
and control littermates (control-Stmn+/+, control-Stmn+/−, and
control-Stmn−/−) (Fig. 1B).
The stathmin levels in spinal cords from postnatal day (PND) 9
mice in each group were analyzed by Western blot. As shown in
Figs. 1C and D, stathmin levels decreased by about 50% in SMA-
Stmn+/− and in control-Stmn+/− mice; stathmin expression was ab-
sent in SMA-Stmn−/− and in control-Stmn−/− mice when compared
to the control groups (control-Stmn+/+ and SMA-Stmn+/+). This
result shows that the stathmin protein levels in each group corre-
sponded to their genotypes (Fig. 1B).
Heterozygous StmnKO but not homozygous StmnKO increases microtubule
density in SMA-like mice
SMA-like mice were previously shown to have about 26% fewer mi-
crotubules per axon than normal mice (Wen et al., 2010).We therefore
askedwhether depletion of stathmin levels could inﬂuencemicrotubule
density in SMA-like mice. Sciatic axons were isolated from SMA-like
mice of each genotype and their littermate controls and determined
the number of microtubules by electron microscopy. There was no sig-
niﬁcant change in microtubule density in the control group (Figs. 2, A
and B) (control-Stmn+/+, 14.15±0.32 vs. control-Stmn+/−, 14.54±
0.26 vs. control-Stmn−/−, 14.42±0.39). In contrast, mice in the
SMA-Stmn+/− group had an increase of 11% and 14% in the average
number of microtubules per axon compared to SMA-Stmn+/+ mice
(12.86±0.31 vs. 11.58±0.28, P=0.0031) and SMA-Stmn−/− mice
(12.86±0.31 vs. 11.22±0.31, P=0.0003) at PND 9 (Figs. 2, A and B).
These results show that expression of Stmn+/−, but not Stmn−/−, led
to the improvement in the microtubule defect that was identiﬁed in
SMA-like mice (Wen et al., 2010).
StmnKO fails to prolong the lifespan of SMA-like mice
In an attempt to address whether down-regulation of stathmin
could be beneﬁcial for SMA-like mice, a series of cross-mating exper-
iments was conducted. Analysis of a total of 181 SMA-like mice born
from 61 litters showed that StmnKO did not confer a survival advan-
tage over SMA-like mice (Fig. 3A). The maximal survival time (MST)
of the SMA-Stmn+/+ and SMA-Stmn−/− mice was 14 and 16 days,
with an average and median survival time of 9 and 10 days, respec-
tively. One mouse in the SMA-Stmn+/− group showed an unexpected
MST of 41 days, but this group still had an average and median sur-
vival time of 10 days.
Additionally, the body weight of mice of each genotype was mea-
sured everymorning. Regardless of genotype, allmice initially exhibited
similar body weights (Fig. 3B). From PND 4 to 14, control littermates
had continually increasing body weights; however, the body weight
gain in SMA-like mice was impaired. Interestingly, the pups in the
StmnKO groups (SMA-Stmn+/− and SMA-Stmn−/−) had increased
body weight compared to SMA-Stmn+/+ mice from PND 9 to 14, and
SMA-Stmn+/− mice differed signiﬁcantly in body weight compared to
SMA-Stmn+/+mice (Fig. 3B, Pb0.05). In contrast, there was no statisti-
cal difference in body weight gain between the three control group ge-
notypes (Fig. 3B, P=0.944). These data indicate that StmnKO improves
body weight gain in SMA-like mice.
Heterozygous StmnKO improves motor activity in SMA-like mice
Although StmnKO does not fully rescue the SMA-like phenotype,
the body weight gain of SMA-like mice with a StmnKO background
Fig. 2. Improvedmicrotubule densities in heterozygous StmnKO SMAmice. (A) Transverse ultrathin sections of sciatic nerve were collected from control (upper) and SMA-like (bottom)
mice at PND 9. Bars, 0.5 μm. (B)Microtubule densities (number ofmicrotubules per axon area) in SMA-likemice and control littermateswere calculated (N=3 per group; the total num-
ber of nerve sections analyzed per group were as follows: control-Stmn+/+ mice, 435; control-Stmn+/−mice, 530; control-Stmn−/−mice, 301; SMA-Stmn+/+ mice, 266; SMA-Stmn+/−
mice, 329; and SMA-Stmn−/−mice, 294). Data are presented as mean±S.E.M. ⁎⁎⁎Pb0.0001 when compared to SMA-Stmn+/+ and SMA-Stmn−/−mice by Student's t-test.
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then assessed the motor activity in each mouse genotype by Tube
assay through PND 3. The motor performance was scored from 4 to
0 based on the hind-limb strength (see details in Materials and
methods section). As expected, the control groups had excellent
motor performance (Fig. 4). Interestingly, SMA-Stmn+/− mice showed
improved motor performance compared to SMA-Stmn+/+ and
SMA-Stmn−/−mice at PND 11 (3.14±0.25 vs. 2.22±0.28, P=0.0271;
3.14±0.25 vs.1.16±0.16, Pb0.0001) and at PND 12 [2.75±0.25
(SMA-Stmn+/− group) vs. 1.75±0.16 (SMA-Stmn+/+ group), P=
0.0081] (Fig. 4). However, SMA-Stmn+/− mice showed deterioration
in motor performance starting at PND13. This result indicates that
Stmn+/− delayed the decline in motor function of SMA-like mice.
Decrease in stathmin levels does not prevent motor neuron death in
SMA-like mice
Since an improvement in the motor performance of Stmn+/−mice
was observed, we asked whether this could be caused by the preven-
tion of motor neuron death due to decreased stathmin levels. Motor
neuron counts were then measured in spinal cord sections from
each genotype of SMA-like and control mice at PND 9 and 12 by
Nissl staining. The results showed no signiﬁcant change in motor neu-
ron numbers between the three genotypes of control mice at PND 9
(control-Stmn+/+, 12.04±0.31 vs. control-Stmn+/−, 12.06±0.34 vs.
control-Stmn−/−, 12.43±0.28) and at PND 12 (control-Stmn+/+,
11.95±0.31 vs. control-Stmn+/−, 11.65±0.18 vs. control-Stmn−/−,
11.74±0.29) (Figs. 5A–D). SMA-like mice had fewer motor neurons
than did control littermates at PND 9 and PND 12 (Figs. 5A–D). No sig-
niﬁcant difference in motor neuron counts were observed between
SMA-Stmn+/+, SMA-Stmn+/−, and SMA-Stmn−/− groups at PND 9
(8.7±0.29 vs. 9.05±0.26 vs. 8.86±0.19, respectively) or at PND 12
(8.87±0.24 vs. 9.43±0.29 vs. 8.87±0.16, respectively) (Figs. 5A–D).
Together, these results show that neither Stmn+/− nor Stmn−/− can
protect motor neurons from death under SMA.In addition, the amount of SMN protein expressed directly correlated
with SMA severity.We analyzed SMNprotein levels in the spinal cords of
mice of each SMA-like genotype and control littermates at PND 9 and
PND 12 by Western blot. Decreased levels of SMN protein expression
were observed in SMA-like mice compared to control littermates
(Figs. 5E and F), and no signiﬁcant differences were seen between mice
in the SMA-Stmn+/+, SMA-Stmn+/−, and SMA-Stmn−/− groups at PND
9 (0.168±0.017 vs. 0.193±0.015 vs. 0.181±0.012, respectively) and
at PND 12 (0.273±0.03 vs. 0.275±0.026 vs.0.269±0.019, respectively)
(Figs. 5A–D). This result indicates that StmnKO does not inﬂuence SMN
production.
Heterozygous StmnKO ameliorates neuromuscular junction (NMJ) defects
in SMA-like mice
To examine whether the observed improvement in motor per-
formance could be attributed to the modiﬁcation of NMJ defects
by decreased stathmin levels, the structure and size of the NMJ
in the tibialis anterior muscle and gastrocnemius muscle in each
genotype of SMA-like mice and control littermates were evaluated
at PND 9 and 12. The NMJ maturation process involves a transition
in acetylcholine receptor (AChR) cluster shape from plaque to pret-
zel morphology and an increase in size. This process was previously
shown to be defective under SMA (Riessland et al., 2010). Post-
synaptic AChRs were visualized by usingα-BTX staining of the mus-
cle. The AChRs were classiﬁed into four morphology types: (1)
Uniform: NMJs are immature and appear as oval plaques with
even distribution of AChRs; (2) Folds: Plaques have bright bands
and form post-synaptic folds; (3) Perforated: Plaques have single
or multiple small holes; (4) Pretzel-like: Plaques have a pretzel-
like shape (Fig. 6A) (Bolliger et al., 2010; Marques et al., 2000).
Here, we combined all genotypes of control mice as the control
group because there was no signiﬁcant difference in their body
weight, motor performance, or motor neuron counts. The results
showed that over 50% of the NMJs were immature, showing uniform
Fig. 4. Motor activity in control and SMA-like mice with different stathmin levels. Motor
performance was assessed by using the Tube test. Note that SMA-Stmn+/−mice showed
better hind-limb strength compared to the SMA-Stmn−/− and SMA-Stmn+/+groups at
later stages of life. ⁎P=0.0135, ⁎⁎P=0.081, and ⁎⁎⁎Pb0.0001 by Student's t-test.
N-values are shown in Fig. 4.
Fig. 3. Absence of Stmn expression cannot prolong the lifespan of SMA-likemice. (A) Sur-
vival analysis of severe SMA-likemicewith different stathmin levels using a Kaplan–Meier
curve. Note that only very few SMA-like mice can survive over 2 weeks in Stmn+/−. (B)
Mean body weight progression in control and SMA-like mice with different stathmin
levels. Note that SMA-Stmn+/− and SMA-Stmn−/− show improved body weight gain.
⁎Pb0.05 compared to SMA-Stmn+/+ by one-way ANOVA (Tukey's multiple comparison
test). N-values are shown in Fig. 3.
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(SMA-Stmn+/+, 58.33%±2.47%; SMA-Stmn+/−, 52.75%±1.27%;
and SMA-Stmn−/−, 60.55%±1.62%) and in the gastrocnemius mus-
cle (SMA-Stmn+/+, 58.72%±2.53%; SMA-Stmn+/−, 53.43%±1.65%;
and SMA-Stmn−/−, 65.31%±0.94%) at PND 9 (Figs. 6, B and C). In
contrast, the control group showed a lower percentage of immature
NMJs in both the tibialis anterior muscle (11.46%±1.3%) and the
gastrocnemius muscle (16.46%±1.12%) (Figs. 6, B and C). As
expected, the percentage of immature NMJs decreased at PND 12 in
both SMA-like mice and control mice (Figs. 6, D and E). Interestingly,
the SMA-Stmn+/− group had a signiﬁcantly lower percentage of
plaques with a uniform structure and a higher percentage with
pretzel-like structure compared to the SMA-Stmn+/+ and SMA-
Stmn−/− groups in both the tibialis anterior muscle (Uniform:
7.16%±1% vs.18.67%±1.68%, P=0.0009; 7.16%±1% vs. 16.76%±
1.16%, P=0.0016; Pretzel-like: 9.15%±0.69% vs. 2.26%±0.42%,
Pb0.0001, and 9.15%±0.69% vs. 2.64%±0.14%, P=0.0005) and in
the gastrocnemius muscle (Uniform: 10.43%±3.44% vs. 31.6%±
2.85%, P=0.003, and 10.43%±3.44% vs. 26.6%±2.77%, P=0.0217;
Pretzel-like: 10.55%±2.2% vs. 0.5%±0.48%, P=0.0012, and
10.55%±2.2% vs. 0.79%±0.79%, P=0.0148) at PND 12 (Figs. 6, D
and E). In addition, the NMJs were signiﬁcantly larger in both the tibialis
anterior and the gastrocnemiusmuscles in the SMA-Stmn+/− group com-
pared to the SMA-Stmn+/+ and SMA-Stmn−/− groups at PND 12 (Figs. 6,F and G). Taken together, these results indicate that Stmn+/− ameliorates
defects in NMJ maturation in SMA-like mice.
Heterozygous StmnKO reduced neuroinﬂammation in SMA-like mice
Neuroinﬂammation is a cellular process induced by microglial and
astroglial activations and participates in the progression of neuronal
degeneration (Papadimitriou et al., 2010). Stathmin has been identi-
ﬁed as an agonist for Toll-like receptor 3 (TLR3)-dependent signaling
in astrocyte and microglia, suggesting a potential link between
stathmin and neuroinﬂammation (Bsibsi et al., 2010). We therefore
investigated whether stathmin dysregulation under SMA possibly in-
duces neuroinﬂammation and contributes to the pathogenesis of
SMA. Lumbar spinal cord sections from SMA-like and control groups
at PND 9 and 12 were stained for GFAP which is the typical method
of examination of gliosis indicative of neuroinﬂammation (Fig. 7).
The result showed that gliosis developed in SMA-Stmn+/+, SMA-
Stmn+/−, and SMA-Stmn−/− groups, but were rarely observed in con-
trol groups at PND 9 at PND 12 (Figs. 7A and B), supporting possible
involvement of neuroinﬂammation in SMApathogenesis. Interestingly,
the SMA-Stmn+/− group revealed milder gliosis than the SMA-Stmn+/+
and SMA-Stmn−/− groups, suggesting that stathmin may be involved in
neuroinﬂammation under SMA conditions.
Discussion
We have previously shown that stathmin levels correlate with the
disease severity in SMA-like mice (Wen et al., 2010). Herein, we show
that reduction (Stmn+/−) but not complete absence (Stmn−/−) of
stathmin resulted in improved motor performance in SMA-like mice.
SMA-Stmn−/−mice as well as SMA-Stmn+/−mice had increased body
weight gain (Fig. 3B), and a few of the SMA-Stmn+/− mice (13 out of
95) survived over 2 weeks (3 out of 39 SMA-Stmn+/+ mice; 4 out of
47 SMA-Stmn−/− mice) (Fig. 3A). Even though one of the SMA-
Stmn+/− mice survived until PND 41, Stmn+/− could not prevent the
death of severe SMA-like mice. In addition, SMA-Stmn+/− increased
the microtubule density and attenuated the defects in the NMJ (Figs. 2
Fig. 5.Motor neuron counts are not affected in StmnKO SMA-like mice. Transverse lumbar spinal cord sections from mice in control and SMA-like groups were stained with Nissl at
PND 9 (A) and 12 (C). Higher magniﬁcation is shown in the upper-right panel. Bars, 500 μm. (B, D) Quantiﬁcation of motor neuron numbers in the spinal cords obtained from (A)
and (C); 30–40 sections from each group were quantiﬁed. Results are reported as the mean±S.E.M; n.s., not signiﬁcant by Student's t-test. N-values are shown in Fig. 5. (E) Western
blot conﬁrms the SMN level in each genotype of mice. β-Actin was used as an internal control. (F) Quantitative analysis of SMN level in (E), showing that SMN level is not signiﬁcant
when compared between all genotypes (N=5 in control and SMA-like groups at PND 9; N=3 at PND 12). Results are reported as the mean±S.E.M. n.s., not signiﬁcant by Student's
t-test.
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axonal pathogenesis of SMA but is not associated with the death of
SMA-like mice. A previous report showed that motor neuron rescue inan inducible severe SMA mouse model improved motor activity but
led to only minimal improvement in survival (Gogliotti et al., 2012).
Cardiac dysfunction, which has been described in an SMA mouse
Fig. 6. Heterozygous StmnKO mice show improvement in NMJ pathology. (A) NMJs were visualized by staining with α-BTX and were classiﬁed by morphology as ‘uniform,’ ‘folds,’
‘perforated,’ or ‘pretzel-like.’ Bar, 10 μm. Quantitative graphs of NMJ structures (mean±S.E.M.) showed the percentage of NMJs in the tibialis anterior muscles (B, D) and the gas-
trocnemius muscles (C, E) from control and SMA-like groups at PND 9 (B, C) and 12 (D, E). At PND 12, SMA-Stmn+/−mice showed an improvement of NMJ maturation compared to
SMA-Stmn−/− or SMA-Stmn+/+ mice. Results are reported as the mean±S.E.M. percentage. P-values were calculated by using Student's t-test. N-values are shown in panels (F, G).
Quantitative plots (mean±S.E.M.) show that NMJs were signiﬁcantly larger in the tibialis anterior and the gastrocnemius muscles of control mice compared to those of the
SMA-like groups at PND 9 and 12 (⁎⁎⁎Pb0.001, Student t-test). The NMJs of SMA-Stmn+/− mice were larger than those of SMA-Stmn−/− or SMA-Stmn+/+ mice at PND 9 and 12
(⁎Pb0.05 and ⁎⁎⁎Pb0.001, Student's t-test). N-values are the same as those shown in panels B–D.
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Fig. 7. Heterozygous StmnKO in SMA-like mice mitigates neuroinﬂammation. Transverse lumbar spinal cord sections from mice in control (left panel) and SMA-like groups (right
panel) were stained with GFAP (green) at PND 9 (A) and 12 (B). Higher magniﬁcation of region surrounding the central canal is shown in the upper-left panel. DAPI was used to
stain nuclei (blue). Bars, 100 μm.
101H.-L. Wen et al. / Neurobiology of Disease 52 (2013) 94–103model (Bevan et al., 2010; Heier et al., 2010) and in several clinical stud-
ies (Hachiya et al., 2005; Rudnik-Schoneborn et al., 2008; Tanaka et al.,
1977), still occurred in motor neuron-rescued SMA mice (Gogliotti et
al., 2012). SMA cardiac defects are believed to be involved in respiratory
distress and death. Together, our results showed that Stmn+/− and
Stmn−/− do not prevent death in SMA-like mice, which may be caused
by cardiac deﬁciencies related to SMA.
Insulin-like growth factor (IGF-1) is a neuroprotective trophic fac-
tor that has been shown to improve disease phenotypes in mouse
models of amyotrophic lateral sclerosis (ALS) (Kaspar et al., 2003)
and spinal and bulbar muscular atrophy (SBMA) (Palazzolo et al.,
2009). A previous study showed that IGF-1 and IGF-binding protein,and acid labile subunit (IGFALS) are downregulated in an SMA
mouse model (Hua et al., 2011). Transgenic IGF-1 expression in mus-
cle resulted in an increase in muscle size, body weight, and lifespan in
an SMA mouse model (Bosch-Marce et al., 2011), suggesting that
IGF-1 protein could be a potential factor for use in SMA therapy. No-
tably, IGF-1 expression is increased in embryonic ﬁbroblasts derived
from Stmn−/− mice (Ringhoff and Cassimeris, 2009), suggesting
that decreased stathmin levels may lead to improvements in SMA pa-
thology by increasing IGF-1 protein levels.
Cytoskeletal defects, such as dysregulation of actin dynamics
(Bowerman et al., 2007, 2010; McWhorter et al., 2003; Nolle et al.,
2011), neuroﬁlament accumulation (Cifuentes-Diaz et al., 2002),
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2010), have been observed in SMA animals and were found to cor-
relate with SMA pathology. In our previous work, we showed that
Stmn-knockdown ameliorated defects in microtubule regrowth
and axon outgrowth in Smn-knockdown cells and microtubule-
based mitochondrial transport in SMA-like motor neuron cultures
(Wen et al., 2010). Here, we show that SMA-Stmn+/− mice had a
higher microtubule density and more mature NMJs than did
SMA-Stmn+/+ or SMA-Stmn−/− mice (Figs. 2 and 6), indicating
that downregulation of aberrant stathmin levels (Fig. 1D, SMA-
Stmn+/+ vs. control-Stmn+/+) partly diminished the defects in
SMA-like mice. Interestingly, SMA-Stmn−/− mice had worse motor
performance (Fig. 4), shorter mean lifespan (Fig. 3A), and fewer ben-
eﬁcial effects over SMA-like mice than did SMA-Stmn+/−mice. Gene
expression proﬁles have revealed that the expression of tubulin
isotypes is altered in Stmn−/− mouse embryonic ﬁbroblasts
(Ringhoff and Cassimeris, 2009). Protein levels of a predominant
neuronal tubulin, the β-III isoform, were decreased in Stmn−/−
cells (Ringhoff and Cassimeris, 2009). In contrast, Stmn+/− cells
showed a protein level pattern similar to that of Stmn+/+ cells
(Ringhoff and Cassimeris, 2009). A lack of developmental defects
in the nervous system of Stmn−/− mice was reported, but those
mice still revealed some axonal changes, and an axonopathy was
found in aging mice (Liedtke et al., 2002). These ﬁndings indicate
that stathmin plays a role in the maintenance of the tubulin pool;
therefore, complete absence of stathmin has negative effects on
the regulation of the microtubule network.
Tissue-speciﬁc depletion or rescue of SMN expression using the
Cre–loxP system in the SMA-like mouse model has been used to dem-
onstrate that motor neuron pathology in SMA is the cell-autonomous
effect of SMN insufﬁciency and provided evidence that defects in
non-neuronal tissue correlate with disease severity (Gogliotti et al.,
2012; Park et al., 2010). Clinical studies also reported that gliosis oc-
curred in the spinal cords and brain stems of SMA patients (Araki et
al., 2003; Garcia-Cabezas et al., 2004; Kuru et al., 2009). These ﬁnd-
ings provide evidence that non-cell autonomous effects may possibly
contribute to SMA pathogenesis. Increased stathmin levels reported
in the brains of multiple sclerosis (MS) patients were identiﬁed in
the microglia, astrocytes, and oligodendrocytes of damaged tissue
during inﬂammation (Bsibsi et al., 2010; Chabas et al., 2001; Liu et
al., 2005). In addition, stathmin has been identiﬁed as an agonist for
TLR3-dependent signaling in astrocytes and microglia and mediates
pro- and anti-inﬂammatory response cytokine secretion (Bsibsi et
al., 2010). Human microglia cells stimulated with stathmin signiﬁ-
cantly induce IL-13 (Bsibsi et al., 2010), which has been shown to in-
duce oxidative stress through NAPDH oxidase and cause the
degeneration of hippocampal neurons (Park et al., 2009). Two of
the cytokines, TNF-α and IL-1β, that are activated in microglia by
stathmin stimulation (Bsibsi et al., 2010) have been reported to
cause neurodegeneration (De Lella Ezcurra et al., 2010; Zhao et al.,
2009). Together, these ﬁndings support that neuroinﬂammation
and oxidative stress could be induced upon abnormal stathmin acti-
vation during SMA.
In conclusion, our data indicate that downregulation of aberrantly
expressed stathmin in SMA-like mice improves NMJ maturation in
the tibialis anterior and the gastrocnemius muscles. This improve-
ment may be due to increased microtubule density in axons, which
contributes to the amelioration of some of the defects associated
with SMA.
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